Tonix Pharmaceuticals Holding Forum: Community User: StefanN19

HC Wainwright 22. jährliche globale Investitionskonferenz zuzuhören Tonix Pharmaceuticals Holding Corp. Präsentation am: 16.09.2020 14:30 Uhr (EDT

Was ist los? Stark

Geht wie ein Donnerwetter

7 mio

Ohne die eigentlich erwarteten News

5,7 mio bis jetzt

Net schlecht und das zur mittags zeit

Von - 1,3 % auf + ca. 8 % vorbörslich gespurungen

8,1 mio ist okay für den Anfang

Immerhin stark

6,7 mio

5,1 mio Handel, die wollen wohl noch nicht so richtig 🤔

Zieht

Drüben über 2 mio Handel bis jetzt

👍

NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001), a study of humoral (antibody) and cellular (T cell) immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19. The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix’s TNX-1800, which is a live replicating, attenuated virus vaccine designed to protect against COVID-19. “This represents a significant milestone for the Company as the data we plan to collect from recovered and asymptomatic COVID-19 volunteers in this study will help inform vaccine development on how to safely provide the same immune responses that others got from recovering from actual SARS-CoV-2 infection,” said Seth Lederman, M.D., President and CEO of Tonix. “Our goal with TNX-1800 is to develop a vaccine that is well tolerated, produces strong, long-lasting immunity, and can be rapidly and broadly deployed. The features of a protective immune response to SARS-CoV-2 remain unknown. But since SARS-CoV-2 is a virus, we believe that T cell responses, in particular T Helper Type 1, or TH1 responses, will play an important, if not dominant, role in protecting against serious illness from COVID-19.”